FibroGen (FGEN) Stock Price, News & Analysis

Company Overview

FibroGen, Inc. (NASDAQ: FGEN) is a biopharmaceutical company focused on the discovery, development and commercialization of therapies that address severe unmet medical needs in the areas of fibrosis and anemia. Since its founding in 1993 and establishment in San Francisco, FibroGen has pursued a research‐driven approach to translate insights from hypoxia biology and fibrotic pathways into novel medicines. The company’s work centers on small molecules and biologics designed to modulate key molecular targets implicated in chronic kidney disease, idiopathic pulmonary fibrosis, muscular dystrophies and oncology.

The company’s lead product is roxadustat, an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHI) for the treatment of anemia in chronic kidney disease. Roxadustat has received approvals in China, Japan and the European Union and is marketed in partnership with Astellas and AstraZeneca outside of China. In addition to roxadustat, FibroGen is developing pamrevlumab, a fully human monoclonal antibody targeting connective tissue growth factor (CTGF), in indications such as idiopathic pulmonary fibrosis, pancreatic cancer and Duchenne muscular dystrophy. FibroGen’s pipeline also includes preclinical programs in other fibrotic and inflammatory diseases.

FibroGen maintains research and development facilities in North America, Asia and Europe, supporting a global network of clinical trials and regulatory activities. The company collaborates with strategic partners to accelerate late‐stage development and commercialization, while internal teams drive early research and translational science. With a presence in key markets around the world, FibroGen aims to bring innovative therapies to patients suffering from debilitating, progressive conditions.

Led by a seasoned executive team with backgrounds in biopharmaceutical R&D, clinical development and global commercialization, FibroGen combines scientific rigor with practical expertise. The company’s leadership has overseen the transition from discovery through approval and launch of its first marketed product, positioning FibroGen as a specialized biopharma player dedicated to improving patient outcomes in chronic and life-threatening diseases.

Key Stats

• Today's Range: $7.11 to $7.72
• 50-Day Range: $5.16 to $8.61
• 52-Week Range: $4.50 to $38.25
• Volume: 59,782 shs
• Average Volume: 76,133 shs
• Market Capitalization: $28.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $250.00
• Consensus Rating: Moderate Buy

FibroGen Stock Analysis - MarketRank™

FibroGen scored higher than 95% of companies evaluated by MarketBeat, and ranked 66th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

FibroGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

FibroGen has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for FibroGen are expected to grow in the coming year, from ($0.80) to ($0.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of FibroGen is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of FibroGen is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.56% of the float of FibroGen has been sold short.

Short Interest Ratio / Days to Cover

FibroGen has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in FibroGen has recently decreased by 11.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

FibroGen does not currently pay a dividend.

Dividend Growth

FibroGen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.84

Percentage of Shares Shorted

4.56% of the float of FibroGen has been sold short.

Short Interest Ratio / Days to Cover

FibroGen has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in FibroGen has recently decreased by 11.00%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

FibroGen has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for FibroGen this week, compared to 1 article on an average week.

Search Interest

3 people have searched for FGEN on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added FibroGen to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, FibroGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $119,485.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.07% of the stock of FibroGen is held by insiders.

Percentage Held by Institutions

72.71% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FGEN Stock Analysis - Frequently Asked Questions

How have FGEN shares performed this year?

FibroGen's stock was trading at $13.2375 at the beginning of the year. Since then, FGEN shares have decreased by 46.0% and is now trading at $7.15.

How were FibroGen's earnings last quarter?

FibroGen, Inc (NASDAQ:FGEN) announced its earnings results on Monday, May, 12th. The biopharmaceutical company reported ($4.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.75 by $4.75. The biopharmaceutical company earned $2.70 million during the quarter, compared to analyst estimates of $2 million.
Read the conference call transcript.

When did FibroGen's stock split?

FibroGen shares reverse split on Tuesday, June 17th 2025.The 1-25 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did FibroGen IPO?

FibroGen (FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

How do I buy shares of FibroGen?

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that FibroGen investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FGEN
• CIK: 921299
• Web: www.fibrogen.com
• Phone: (415) 978-1200
• Fax: 415-978-1902
• Employees: 570
• Year Founded: N/A

Price Target and Rating

• Average Price Target for FibroGen: $250.00
• High Price Target: $250.00
• Low Price Target: $250.00
• Potential Upside/Downside: +3,396.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.58 million
• Net Margins: -9.73%
• Pretax Margin: -117.74%
• Return on Equity: N/A
• Return on Assets: -24.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.02
• Quick Ratio: 1.98

Sales & Book Value

• Annual Sales: $7.00 million
• Price / Sales: 4.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($50.89) per share
• Price / Book: -0.14

Miscellaneous

• Outstanding Shares: 4,042,000
• Free Float: 3,918,000
• Market Cap: $28.90 million
• Optionable: Optionable
• Beta: 0.74